Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer

被引:42
作者
Anari, Fern [1 ]
Ramamurthy, Chethan [1 ]
Zibelman, Matthew [1 ]
机构
[1] Fox Chase Canc Ctr Temple Hlth, Philadelphia, PA USA
关键词
biomarkers; immunotherapy; molecular oncology; oncogenes; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; PHASE-II TRIAL; INTERFERON-ALPHA; TRYPTOPHAN CATABOLISM; METASTATIC MELANOMA; PANCREATIC-CANCER; DOUBLE-BLIND; INTERLEUKIN-2; FIBROBLASTS;
D O I
10.2217/fon-2017-0585
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor microenvironment (TME) plays an important role in cancer growth and progression. Paradoxically, the TME is capable of acting as both a potential barrier and facilitator of tumor proliferation by affecting various processes including local growth resistance, immune system interactions, and the formation of distant metastases. This important interaction between cancer cells and their local environment, composed of immune cells, angiogenic cells, lymphatic endothelial cells and cancer-associated fibroblasts is paramount to determine a cancer cell's ability to grow and ultimately metastasize. It is essential to understand this complex interplay in order to define treatment modalities to target the TME as part of anti-cancer therapy. [GRAPHICS]
引用
收藏
页码:1409 / 1421
页数:13
相关论文
共 101 条
  • [1] Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
    Aida, Kouichirou
    Miyakawa, Reina
    Suzuki, Koji
    Narumi, Kenta
    Udagawa, Takeshi
    Yamamoto, Yuki
    Chikaraishi, Tatsuya
    Yoshida, Teruhiko
    Aoki, Kazunori
    [J]. CANCER SCIENCE, 2014, 105 (02) : 159 - 167
  • [2] Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review
    Al-Abd, Ahmed M.
    Alamoudi, Abdulmohsin J.
    Abdel-Naim, Ashraf B.
    Neamatallah, Thikryat A.
    Ashour, Osama M.
    [J]. JOURNAL OF ADVANCED RESEARCH, 2017, 8 (06) : 591 - 605
  • [3] Amin A, 2013, J CLIN ONCOL S, V31
  • [4] [Anonymous], 2015, J CLIN ONCOL S
  • [5] [Anonymous], CLIN CANC RES
  • [6] [Anonymous], J CLIN ONTOL
  • [7] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [8] Badruddoja MA, 2004, J CLIN ONCOL, V22, p124S
  • [9] The rationale for targeting the LOX family in cancer
    Barker, Holly E.
    Cox, Thomas R.
    Erler, Janine T.
    [J]. NATURE REVIEWS CANCER, 2012, 12 (08) : 540 - 552
  • [10] Cancer-specific Survival Outcomes Among Patients Treated During the Cytokine Era of Kidney Cancer (1989-2005) A Benchmark for Emerging Targeted Cancer Therapies
    Belldegrun, Arie S.
    Klatte, Tobias
    Shuch, Brian
    LaRochelle, Jeffrey C.
    Miller, David C.
    Said, Jonathan W.
    Riggs, Stephen B.
    Zomorodian, Nazy
    Kabbinavar, Fairooz F.
    deKernion, Jean B.
    Pantuck, Allan J.
    [J]. CANCER, 2008, 113 (09) : 2457 - 2463